To provide an update on the COVID spike and response in India over the past 6 weeks since Chadi’s previous episode, Aju Mathew, MD, oncologist practicing in southern India, joins the show. Dr. Mathew begins by describing the tradeoffs of moving home to practice in India while leaving his academic career behind in the US, offers critical remarks on India’s government use of resources to combat COVID up to and during the “tsunami,” shares how vaccine hesitancy around the world bled into India’s population, provides a status on the current vaccine and resource availability in the country as well as the percentage of the population vaccinated, and plenty more.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
